Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Chen, Weibo ^a,b   Wu, Junhua ^c   Shi, Hua ^c   Wang, Zhongxia ^a,b   Zhang, Guang ^b,d   Cao, Yin ^a,b   Jiang, Chunping ^a,b,d   Ding, Yitao ^a,b,d  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^b Jiangsu Province's Key Medical Center for Hepatobiliary Disease   (China)

^c NANJING UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CRIZOTINIB; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; S 3I 201; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SORAFENIB; STAT3 PROTEIN; TOFACITINIB; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; CULTURE MEDIUM; JAK2 PROTEIN, HUMAN; LIGAND; NICOTINAMIDE; STAT3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CULTURE; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REACTIVATION; FLUORESCENCE MICROSCOPY; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; MTT ASSAY; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; STELLATE CELL; SUPERNATANT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; CULTURE MEDIA; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATIC STELLATE CELLS; HUMANS; JANUS KINASE 2; LIGANDS; LIVER NEOPLASMS; MICROSCOPY, FLUORESCENCE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84904112646     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/764981     Document Type: Article

References (24)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA: Cancer Journal for Clinicians 2011 61 2 69 90 10.3322/caac.20107 2-s2.0-79952232216
2. El-Serag H. B., Rudolph K. L., Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 7 2557 2576 10.1053/j.gastro.2007.04.061 2-s2.0-34250020201 (Pubitemid 46890874)
3. El-Serag H. B., Hepatocellular carcinoma. The New England Journal of Medicine 2011 365 12 1118 1127 10.1056/NEJMra1001683 2-s2.0-80053088189
4. Moritz A., Li Y., Guo A., Villén J., Wang Y., MacNeill J., Kornhauser J., Sprott K., Zhou J., Possemato A., Ren J. M., Hornbeck P., Cantley L. C., Gygi S. P., Rush J., Comb M. J., Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Science Signaling 2010 3 136 ra64 10.1126/scisignal.2000998 2-s2.0-77956621143
5. Wilson T. R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., Peng J., Lin E., Wang Y., Sosman J., Ribas A., Li J., Moffat J., Sutherlin D. P., Koeppen H., Merchant M., Neve R., Settleman J., Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012 487 7408 505 509 10.1038/nature11249 2-s2.0-84864286442
6. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z. R., Du J., Davis A., Mongare M. M., Gould J., Frederick D. T., Cooper Z. A., Chapman P. B., Solit D. B., Ribas A., Lo R. S., Flaherty K. T., Ogino S., Wargo J. A., Golub T. R., Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012 487 7408 500 504 10.1038/nature11183 2-s2.0-84864285794
7. Nasser M. W., Datta J., Nuovo G., Kutay H., Motiwala T., Majumder S., Wang B., Suster S., Jacob S. T., Ghoshal K., Down-regulation of micro-RNA-1 (miR-1) in lung cancer: suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. The Journal of Biological Chemistry 2008 283 48 33394 33405 10.1074/jbc.M804788200 2-s2.0-57749089758
8. Yu G., Jing Y., Kou X., Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma. PloS ONE 2013 8 9 e73312 10.1371/journal.pone.0073312
9. Chen K.-F., Chen H.-L., Tai W.-T., Feng W.-C., Hsu C., Chen P., Cheng A., Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. Journal of Pharmacology and Experimental Therapeutics 2011 337 1 155 161 10.1124/jpet.110.175786 2-s2.0-79952995316
10. Bean J., Brennan C., Shih J., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., Balak M., Chang W., Yu C., Gazdar A., Pass H., Rusch V., Gerald W., Huang S., Yang P., Miller V., Ladanyi M., Yang C., Pao W., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America 2007 104 52 20932 20937 10.1073/pnas.0710370104 2-s2.0-38049150665
11. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., Carter C., Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research 2006 66 24 11851 11858 10.1158/0008-5472.CAN-06-1377 2-s2.0-33846212284 (Pubitemid 46094197)
12. He G., Karin M., NF- B and STAT3- key players in liver inflammation and cancer. Cell Research 2011 21 1 159 168 10.1038/cr.2010.183 2-s2.0-78650859531
13. Li Z., Dalton W. S., Tumor microenvironment and drug resistance in hematologic malignancies. Blood Reviews 2006 20 6 333 342 10.1016/j.blre.2005. 08.003 2-s2.0-33750631842 (Pubitemid 44691998)
14. Cecchi F., Rabe D. C., Bottaro D. P., Targeting the HGF/Met signalling pathway in cancer. European Journal of Cancer 2010 46 7 1260 1270 10.1016/j.ejca.2010.02.028 2-s2.0-77950552463
15. Corcoran R. B., Settleman J., Engelman J. A., Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK Inhibitors in BRAF mutant cancers. Oncotarget 2011 2 4 336 346 2-s2.0-80053307869
16. Yang F., Brown C., Buettner R., Hedvat M., Starr R., Scuto A., Schroeder A., Jensen M., Jove R., Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Molecular Cancer Therapeutics 2010 9 4 953 962 10.1158/1535-7163.MCT-09-0947 2-s2.0-77950833182
17. Huang S., Sinicrope F. A., Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Molecular Cancer Therapeutics 2010 9 3 742 750 10.1158/1535-7163.MCT-09-1004 2-s2.0-77949686312
18. Chen K., Tai W., Liu T., Huang H., Lin Y., Shiau C., Li P., Chen P., Cheng A., Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clinical Cancer Research 2010 16 21 5189 5199 10.1158/1078-0432.CCR-09-3389 2-s2.0-78049465993
19. Liu C., Tseng L., Su J., Chang K., Chu P., Tai W., Shiau C., Chen K., Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Research 2013 15 article R63 10.1186/bcr3457 2-s2.0-84881269149
20. Gu F.-M., Li Q.-L., Gao Q., Jiang J.-H., Huang X.-Y., Pan J.-F., Fan J., Zhou J., Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World Journal of Gastroenterology 2011 17 34 3922 3932 10.3748/wjg.v17.i34.3922 2-s2.0-80054808967
21. Tai W., Cheng A., Shiau C., Huang H., Huang J., Chen P., Chen K., Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. Journal of Hepatology 2011 55 5 1041 1048 10.1016/j.jhep.2011.01.047 2-s2.0-80054738311
22. Wang X., Goldstein D., Crowe P. J., Yang J.-L., S3I-201, a novel STAT3 inhibitor, inhibits growth of human soft tissue sarcoma cell lines. World Journal of Cancer Research 2013 1 1 61 68 10.1166/wjcr.2013.1005
23. Lin L., Amin R., Gallicano G. I., Glasgow E., Jogunoori W., Jessup J. M., Zasloff M., Marshall J. L., Shetty K., Johnson L., Mishra L., He A. R., The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF- β signaling. Oncogene 2009 28 7 961 972 10.1038/onc.2008.448 2-s2.0-60549108333
24. Jaganathan S., Yue P., Paladino D. C., Bogdanovic J., Huo Q., Turkson J., A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS ONE 2011 6 5 e19605 10.1371/journal.pone.0019605 2-s2.0-79955799333